South Africa pushes for local HIV drug production

South Africa is spearheading a drive to bring the production of Gilead Sciences' long-acting HIV prevention drug, lenacapavir, to the region. The government is working with international collaborators, including Unitaid and the United States Pharmacopoeia, to identify local pharmaceutical companies capable of producing the twice-yearly injection safely, effectively, and affordably.

This move comes as Gilead has already granted voluntary licenses to generic manufacturers in India, Egypt, and Pakistan for distribution to 120 low- and middle-income countries. A license for a South African company would mark the seventh such agreement, potentially enhancing access to a drug that experts believe could help end the HIV pandemic by reducing new infections.

The African region continues to be the epicenter of the HIV pandemic, with South Africa having the highest number of affected individuals, approximately 8 million. The push for local manufacturing, supported by African leaders, aims to reduce reliance on medicines produced elsewhere for diseases disproportionately affecting the continent.

Past access challenges for HIV drugs in low- and middle-income countries highlight the importance of this initiative. While lenacapavir is available in some African nations, demand is expected to rise. Establishing local production could also potentially expand access to countries like Brazil, further addressing global health equity.